In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Similarly, zinc may contribute to GI issues like diarrhea or cramping. Many immune-supporting supplements combine vitamin C ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield ...

With evidence from 85,373 participants across 11 trials, GLP-1 receptor agonists significantly reduced kidney failure risk and cardiovascular events, showing consistent benefits across diabetes ...

GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...

With the growing demand for GLP-1 drugs for weight loss, a high percentage of medication users are experiencing temporary and long-term side effects from these rapid weight loss methods. Kelker Pharma ...